We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

MaxCyte

Extension of clinical and commercial license with CRISPR Therapeutics

Lighthouse | 09 November 2018

Bonesupport

Stronger commercial platform to make strategic inroads

Update | 08 November 2018

Mereo BioPharma

Phase II starts with backing from patient support group

Lighthouse | 05 November 2018

Nexstim

Navigating the opportunity in depression

Update | 11 October 2018

MaxCyte

Major milestone achieved, as first patient is treated with a CARMA product

Lighthouse | 10 October 2018

BerGenBio

New data support potential in NSCLC

Update | 09 October 2018

e-therapeutics

Progress in all areas, and a longer cash runway

Lighthouse | 04 October 2018

Bonesupport

Putting more flesh on the bones

Update | 01 October 2018

Mereo BioPharma

Raring to go in rare diseases

Initiation | 24 September 2018

MaxCyte

Core business continues to deliver, as CARMA enters the clinic

Lighthouse | 24 September 2018
1 2 3 4 5 6 7 8 9 10
98 results found.